Antibiotics Market Opportunity: Novel Products Needed for Drug-Resistant Bacteria Threat
• Rising drug-resistant infection cases to drive antibiotics market growth
• Upcoming regulatory reform 'will facilitate more efficient clinical development programs,' says analyst
Antibiotics Market Opportunity: Novel Products Needed for Drug-Resistant Bacteria Threat
LONDON, UK (GlobalData), 28 August 2013 - Rising demand for antibiotics to counter increasing cases of drug-resistant infections, combined with decreasing Research and Development (R&D) costs, is presenting an ideal opportunity for pharmaceutical manufacturers to launch novel products into the marketplace, according to a new report from GlobalData.
The company’s latest report* states that over the coming years, the growing level of threat posed by multidrug-resistant (MDR) bacteria, particularly gram-negative organisms, will be a key driver behind the growth of the antibiotics market in the US, France, Italy, Germany, Spain and the UK.
A stagnant antibiotic pipeline has escalated medical concerns caused by MDR bacteria in these countries, and a significant unmet need exists for novel antibiotics to counter the problem.
However, low returns on investment (ROIs), primarily caused by expensive R&D processes and convoluted regulatory requirements, have been deterring drug manufacturers from developing new products, according to the report.
Christopher Pace, Ph.D., GlobalData’s Analyst covering Infectious Disease, explains: “Many large pharmaceutical companies have previously abandoned antibiotics due to the drugs’ risky and prolonged R&D processes. However, we can now expect to see upcoming regulatory reform on clinical trial design, led by guidance from the Food and Drug Administration and the European Medicines Agency, which will facilitate more efficient clinical development programs and reduce a number of barriers to market entry.”
Brad Tebbets, Ph.D., GlobalData’s Infectious Disease Analyst, concludes: “Future financial backing from governments will also play a key role in all stages of the R&D process, helping to decrease the cost of antibiotic development and therefore better enabling more companies to launch new products that address the current unmet clinical need. More specifically, public-private partnerships (PPPs) represent an alternative business model that effectively aligns clinical and commercial needs.”
As a result, regulators, pharmaceutical companies and physicians are now working more closely than ever to remove a number of obstacles for keen developers.
*PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria
-ENDS-
-NOTES TO EDITORS-
This report provides an overview of incentive mechanisms and programs designed to encourage antibiotic R&D, as well as current regulatory trends and the role of academia, small and medium enterprises and Big Pharma in bringing next-generation antibiotics to market. It also provides analysis of the key industry drivers, restraints and challenges in the US and 5EU.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
-ABOUT GLOBALDATA-
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.
• Upcoming regulatory reform 'will facilitate more efficient clinical development programs,' says analyst
Antibiotics Market Opportunity: Novel Products Needed for Drug-Resistant Bacteria Threat
LONDON, UK (GlobalData), 28 August 2013 - Rising demand for antibiotics to counter increasing cases of drug-resistant infections, combined with decreasing Research and Development (R&D) costs, is presenting an ideal opportunity for pharmaceutical manufacturers to launch novel products into the marketplace, according to a new report from GlobalData.
The company’s latest report* states that over the coming years, the growing level of threat posed by multidrug-resistant (MDR) bacteria, particularly gram-negative organisms, will be a key driver behind the growth of the antibiotics market in the US, France, Italy, Germany, Spain and the UK.
A stagnant antibiotic pipeline has escalated medical concerns caused by MDR bacteria in these countries, and a significant unmet need exists for novel antibiotics to counter the problem.
However, low returns on investment (ROIs), primarily caused by expensive R&D processes and convoluted regulatory requirements, have been deterring drug manufacturers from developing new products, according to the report.
Christopher Pace, Ph.D., GlobalData’s Analyst covering Infectious Disease, explains: “Many large pharmaceutical companies have previously abandoned antibiotics due to the drugs’ risky and prolonged R&D processes. However, we can now expect to see upcoming regulatory reform on clinical trial design, led by guidance from the Food and Drug Administration and the European Medicines Agency, which will facilitate more efficient clinical development programs and reduce a number of barriers to market entry.”
Brad Tebbets, Ph.D., GlobalData’s Infectious Disease Analyst, concludes: “Future financial backing from governments will also play a key role in all stages of the R&D process, helping to decrease the cost of antibiotic development and therefore better enabling more companies to launch new products that address the current unmet clinical need. More specifically, public-private partnerships (PPPs) represent an alternative business model that effectively aligns clinical and commercial needs.”
As a result, regulators, pharmaceutical companies and physicians are now working more closely than ever to remove a number of obstacles for keen developers.
*PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria
-ENDS-
-NOTES TO EDITORS-
This report provides an overview of incentive mechanisms and programs designed to encourage antibiotic R&D, as well as current regulatory trends and the role of academia, small and medium enterprises and Big Pharma in bringing next-generation antibiotics to market. It also provides analysis of the key industry drivers, restraints and challenges in the US and 5EU.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
-ABOUT GLOBALDATA-
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.
No hay comentarios:
Publicar un comentario